HRP20190147T1 - Benzoksazinon amidi kao modulatori mineralokortikodnih receptora - Google Patents
Benzoksazinon amidi kao modulatori mineralokortikodnih receptoraInfo
- Publication number
- HRP20190147T1 HRP20190147T1 HRP20190147TT HRP20190147T HRP20190147T1 HR P20190147 T1 HRP20190147 T1 HR P20190147T1 HR P20190147T T HRP20190147T T HR P20190147TT HR P20190147 T HRP20190147 T HR P20190147T HR P20190147 T1 HRP20190147 T1 HR P20190147T1
- Authority
- HR
- Croatia
- Prior art keywords
- receptor modulators
- mineralocorticoid receptor
- benzoxazinone
- amides
- benzoxazinone amides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 | |
| EP15736015.7A EP3160948B1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
| PCT/GB2015/051860 WO2016001631A1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190147T1 true HRP20190147T1 (hr) | 2019-03-22 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190147TT HRP20190147T1 (hr) | 2014-06-30 | 2019-01-22 | Benzoksazinon amidi kao modulatori mineralokortikodnih receptora |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (hr) |
| EP (1) | EP3160948B1 (hr) |
| JP (1) | JP6368383B2 (hr) |
| KR (1) | KR102012222B1 (hr) |
| CN (1) | CN106536491B (hr) |
| AR (1) | AR101036A1 (hr) |
| AU (1) | AU2015282450C1 (hr) |
| CA (1) | CA2953655C (hr) |
| CY (1) | CY1121596T1 (hr) |
| DK (1) | DK3160948T3 (hr) |
| EA (1) | EA029518B1 (hr) |
| ES (1) | ES2707726T3 (hr) |
| HR (1) | HRP20190147T1 (hr) |
| HU (1) | HUE042370T2 (hr) |
| LT (1) | LT3160948T (hr) |
| ME (1) | ME03316B (hr) |
| MX (1) | MX367404B (hr) |
| PL (1) | PL3160948T3 (hr) |
| PT (1) | PT3160948T (hr) |
| RS (1) | RS58274B1 (hr) |
| SI (1) | SI3160948T1 (hr) |
| TR (1) | TR201900659T4 (hr) |
| TW (1) | TWI677498B (hr) |
| UY (1) | UY36195A (hr) |
| WO (1) | WO2016001631A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58274B1 (sr) * | 2014-06-30 | 2019-03-29 | Astrazeneca Ab | Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora |
| EA202190226A1 (ru) | 2018-07-19 | 2021-06-16 | Астразенека Аб | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| JP2022530575A (ja) | 2019-08-30 | 2022-06-30 | アストラゼネカ・アクチエボラーグ | ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法 |
| WO2022022865A1 (en) | 2020-07-27 | 2022-02-03 | Astrazeneca Ab | Methods of treating chronic kidney disease with dapagliflozin |
| CA3222502A1 (en) | 2021-06-15 | 2022-12-22 | Lingyun Wu | Benzoxazinone derivatives |
| WO2024015425A1 (en) | 2022-07-14 | 2024-01-18 | Fmc Corporation | Herbicidal benzoxazines |
| WO2024047574A1 (en) | 2022-09-01 | 2024-03-07 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004528335A (ja) * | 2001-04-23 | 2004-09-16 | アストラゼネカ アクチボラグ | 血管新生の治療に使用のベンゾオキサジノン誘導体 |
| WO2004056820A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| EP1778233A1 (en) * | 2004-07-14 | 2007-05-02 | Ligand Pharmaceuticals, Inc. | Intracellular receptor modulator compounds and methods |
| CN101365696A (zh) * | 2004-07-28 | 2009-02-11 | Irm责任有限公司 | 作为类固醇激素核受体调节剂的化合物和组合物 |
| JP2009523701A (ja) | 2005-12-28 | 2009-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| AP2527A (en) | 2006-10-31 | 2012-12-06 | Pfizer Prod Inc | Pyrazoline compounds as mineralocorticoid receptorantagonists |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| AU2008230115A1 (en) | 2007-03-23 | 2008-10-02 | Merck Sharp & Dohme Corp. | Mineralocorticoid receptor modulators |
| TWI444185B (zh) | 2007-04-09 | 2014-07-11 | Daiichi Sankyo Co Ltd | 吡咯衍生物之阻轉異構物 |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| AU2009260899B2 (en) * | 2008-06-18 | 2012-02-23 | Astrazeneca Ab | Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| AU2010222902B2 (en) | 2009-03-12 | 2013-04-18 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
| US20120022058A1 (en) | 2009-04-10 | 2012-01-26 | Pfizer Inc. | 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses |
| CA2798831A1 (en) | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
| US8979337B2 (en) | 2010-05-11 | 2015-03-17 | Koninklijke Philips N.V. | Lighting module |
| TW201216957A (en) | 2010-07-13 | 2012-05-01 | Dainippon Sumitomo Pharma Co | Biarylamide derivative or a pharmaceutically acceptable salt thereof |
| WO2012064631A1 (en) | 2010-11-10 | 2012-05-18 | Boehringer Ingelheim International Gmbh | Pyridyl ureas as mineralocorticoid receptor antagonists |
| RS58274B1 (sr) * | 2014-06-30 | 2019-03-29 | Astrazeneca Ab | Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora |
-
2015
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en active Application Filing
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active IP Right Grant
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-22 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
| HRP20190147T1 (hr) | Benzoksazinon amidi kao modulatori mineralokortikodnih receptora | |
| HK1255160A1 (zh) | 取代的4-氮雜吲哚以及它們作為glun2b受體調節劑的用途 | |
| ZA201700342B (en) | Novel glp-1 receptor modulators | |
| PT2937137T (pt) | Máquina misturadora | |
| IL249267A0 (en) | Materials containing carbonitrile and their use for selective modulation of the androgen receptor | |
| AU357894S (en) | Mixer | |
| EP3140625C0 (en) | MIXING DEVICE | |
| GB201407093D0 (en) | Stand mixer controls | |
| GB201409933D0 (en) | Novel device | |
| HK1245291A1 (zh) | 針對纖連蛋白-eda的免疫球蛋白樣分子 | |
| IL252565B (en) | New receptor modulators | |
| AP2017009818A0 (en) | Saturator | |
| GB2531886B (en) | Attaching apparatus | |
| GB2529821B (en) | Tensioning device | |
| GB201417920D0 (en) | Proportional mixing device | |
| GB201411509D0 (en) | Stand mixers | |
| GB201411512D0 (en) | Stand mixers | |
| GB201416514D0 (en) | Mixing device | |
| GB201405403D0 (en) | Receptor modulation | |
| GB201411548D0 (en) | Mixing device | |
| GB201421354D0 (en) | Tensioning device | |
| GB201417160D0 (en) | Attaching apparatus | |
| GB201415940D0 (en) | Attaching Apparatus | |
| GB201417040D0 (en) | Novel device |